Neuca

Neuca Stock-Based Compensation

The Stock-Based Compensation (SBC) of Neuca (NEU.WA) as of Oct 21, 2026 is 14.91 M PLN. In the previous year, Stock-Based Compensation (SBC) was 18.74 M PLN — a change of -20.43% (lower).

Stock-Based Compensation

14.91 MPLN

YoY

-20.43%

Last updated:

Stock-Based Compensation (SBC) of Neuca is 2025 14.91 M PLN. Stock-Based Compensation (SBC) of Neuca was 2024 18.74 M PLN. It decreases by -20.43% lower compared to the previous year.

The Neuca Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
3.91 M PLN
Jan 1, 2019
3.94 M PLN
Jan 1, 2020
5.16 M PLN
Jan 1, 2021
10.55 M PLN
Jan 1, 2022
11.28 M PLN
Jan 1, 2023
9.96 M PLN
Jan 1, 2024
18.74 M PLN
Jan 1, 2025
14.91 M PLN
The Neuca Stock-Based Compensation history
YEARStock-Based CompensationYoY
14.91 MPLN-20.43%
18.74 MPLN+88.13%
9.96 MPLN-11.74%
11.28 MPLN+6.96%
10.55 MPLN+104.46%
5.16 MPLN+30.83%
3.94 MPLN+0.90%
3.91 MPLN-4.73%
4.10 MPLN-31.26%
5.97 MPLN+58.92%
3.76 MPLN+327.79%
878,000.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

Stock-Based Compensation (SBC) of Neuca is 14.91 M PLN in 2025.

Stock-Based Compensation (SBC) of Neuca changed from 18.74 M PLN to 14.91 M PLN, representing a -20.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Neuca since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Neuca historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Neuca

All Key Metrics — Neuca